Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease

Author(s): Jerzy Leszek, Elzbieta Trypka, Vadim V. Tarasov, Ghulam Md Ashraf, Gjumrakch Aliev

Journal Name: Current Topics in Medicinal Chemistry

Volume 17 , Issue 12 , 2017

Become EABM
Become Reviewer


The brain of patients with Alzheimer disease (AD) showed the evidence of reduced expression of insulin and neuronal insulin receptors, as compared with those of age-matched controls. This event gradually and certainly leads to a breakdown of the entire insulin-signaling pathway, which manifests insulin resistance. This in turn affects brain metabolism and cognitive functions, which are the bestdocumented abnormalities in AD. These observations led Dr. de la Monte and her colleagues to suggest that AD is actually a neuroendocrine disorder that resembles type 2 diabetes mellitus. The truth would be more complex with understanding the role of low-density lipoprotein receptor-related protein 1, Aβ derived diffusible ligands, and advanced glycation end products. However, now it known as “brain diabetes” and is called type 3 diabetes mellitus (T3DM). This review provides an overview of “brain diabetes” focusing on the reason why the phenomenon is called T3DM.

Keywords: Alzheimer disease, Diabetes mellitus, Insulin, Type 2 diabetes mellitus, Type 3 diabetes mellitus.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1331 - 1335]
Pages: 5
DOI: 10.2174/1568026617666170103163403
Price: $65

Article Metrics

PDF: 99
HTML: 15